Review



elisa  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems elisa
    Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 197 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/Human+Renin+DuoSet+ELISA/pm38161127-35-5-7
    Average 95 stars, based on 197 article reviews
    elisa - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Chimeric antigen receptor therapies for treating solid tumors
    Article Snippet: .. Then, 100 uL of supernatant was collected and subject to analysis for human TGFβ1 employing Duoset ELISA for human TGFβ1 (R&D Systems) following the manufacturer's instructions. ..

    Article Title: Directed evolution–driven reprogramming of PD-L1 for compact and tunable checkpoint modulation
    Article Snippet: RPMI 1640 medium, fetal bovine serum (FBS), antibiotic-antimycotic, sodium pyruvate, MEM non-essential amino acids solution, FreeStyle 293 expression medium, and Alexa Fluor 488 protein labeling kit were supplied by Thermo Fisher Scientific (Waltham, MA, USA). .. Interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and human cytokine DuoSet ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). .. Interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were obtained from Peprotech (Cranbury, NJ, USA).

    Article Title: Telomerase modRNA Offers a Novel RNA ‐Based Approach to Treat Human Pulmonary Fibrosis
    Article Snippet: PCLS culture supernatants were collected after 96 h, supplemented with 0.2% protease inhibitor cocktail (87,785 Thermo Fisher Scientific), and stored at −80°C. .. Human IL6, IL8, TGFβ and pro‐COL1A1 were measured using DuoSet ELISA kits from R&D Systems (DY206, DY208, DY6220 and DY240) according to the manufacturer's recommendations. .. Broad panel of immune cytokines was measured using V‐PLEX Pro‐inflammatory Panel 1 Human Kit (K15049D, Meso Scale Diagnostics) according to manufacturer's recommendations.

    Article Title: TREM-1: A potential prognostic marker in newborns with late-onset sepsis.
    Article Snippet: Background: Diagnosing late-onset neonatal sepsis (LOS) continues to be a complex task, highlighting the need for continued research to discover reliable biomarkers that can improve both diagnostic accuracy and prognostic evaluation.. This experimental prospective cohort study aimed to assess the potential of TREM-1 as a diagnostic and prognostic marker for LOS.. Methods: This study included 121 newborns (NBs) distributed as follows: 84 blood samples from NBs with LOS, categorized into Gram-negative sepsis, Gram-positive sepsis, and culture-negative sepsis groups, along with 37 infection-free controls. sTREM-1 levels were measured using an immunoenzymatic assay on samples collected at diagnosis and on days 3 and 7 afterward, while TREM1 gene expression was assessed by RT-qPCR on the day of

    Article Title: Insight into immunoregulatory and neuromodulatory capability of Bacteroides cellulosilyticus and Bacteroides xylanisolvens human gut microbiota isolates.
    Article Snippet: .. Cytokines measurement Following co-culture of Caco-2 and PBMCs and a 24-hour exposure to Bacteroides strains, supernatant from the apical side of the differentiated Caco-2 cells, were collected for the quantification of IL-8, while PBMCs supernatants were collected for the quantification of TNF-α, IL-6, IL-8, and IL-1β using the Human DuoSet ELISA kit (R&D Systems, USA) following the manufacturer’s protocol. .. The optical density of each sample was measured at 450 nm and 570 nm using an Infinite Multimode Reader (Tecan).

    Article Title: The Anti-EMMPRIN Monoclonal Antibody hMR18-mAb Induces Tumor Dormancy and Inhibits the EMT Process in Human Carcinoma Cell Lines Co-Cultured with Macrophages.
    Article Snippet: .. The concentrations of TNFα, IGF-1, TGFβ, MMP-9, VEGF, and EMMPRIN in the supernatants of the cultures were determined using the human DuoSet ELISA kits, according to the manufacturer’s instructions (R&D systems). ..

    Recombinant:

    Article Title: Electrochemical Tracking of Macrophage Migration Inhibitory Factor: A Leap Toward Precision Colorectal Cancer Diagnosis and Prognosis
    Article Snippet: .. In addition, the supplier company (DuoSet ELISATM, R&D Systems) certified the absence of cross-reactivity or interference for the recombinant human IFN-γ and IL-4, or mouse MIF proteins, all of which were assayed at 50 ng mL −1 . ..



    Similar Products

    90
    R&D Systems neutralizing antibodies against sflt-1
    Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and <t>sFlt-1</t> in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.
    Neutralizing Antibodies Against Sflt 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/vegf+elisa+kit/pmc06886281-71-30-35
    Average 90 stars, based on 1 article reviews
    neutralizing antibodies against sflt-1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

    Journal: Journal of Tissue Engineering

    Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

    doi: 10.1177/2041731419891256

    Figure Lengend Snippet: Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

    Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

    Techniques: Recombinant, Injection, Expressing

    sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.

    Journal: Journal of Tissue Engineering

    Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

    doi: 10.1177/2041731419891256

    Figure Lengend Snippet: sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.

    Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

    Techniques: Angiogenesis Assay